36 completed. 36 Phase 2, 15 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 36 | Completed 36 |
| Phase 1 | 15 | Completed 15 |
| Phase 3 | 1 | Completed 1 |
Follow Hematologic Malignancies: new trials by email Literature Review of Hematologic Malignancies trials Research Report on Hematologic Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152 - Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2023-04-05 | 2026-02-23 |
| A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma Teclistamab - Hematologic Malignancies | Phase 1 / Phase 2 | Completed | Janssen Pharmaceutical K.K. | 40 | 2021-02-22 | 2026-06-05 |
| Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease Tildrakizumab - Hematologic Malignancies | Phase 2 | Completed | Medical College of Wisconsin | 51 | 2020-03-01 | 2025-10-21 |
| Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT Haplo HCT <55 years old, Haplo HCT ≥55 years old, GVHD Prophylaxis - Hematologic Malignancies | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 78 | 2017-01-24 | 2025-05-28 |
| Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies ProTmune, Control Arm - Hematologic Malignancies, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Fate Therapeutics | 96 | 2016-12-20 | 2023-02-08 |
| A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders CC-486 - Hematologic Neoplasm, Neoplasms | Phase 2 | Completed | Celgene | 5 | 2015-10-22 | 2026-04-02 |
| Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Carfilzomib, Tacrolimus - Hematologic Malignancies, Relapse | Phase 1 / Phase 2 | Completed | University of Michigan Rogel Cancer Center | 53 | 2014-10-01 | 2022-01-03 |
| Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy Cyclophosphamide - Hematologic Malignancies | Phase 2 | Completed | Dartmouth-Hitchcock Medical Center | 58 | 2013-12-01 | 2021-02-16 |
| Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation CliniMACS® CD34 Reagent System, Fludarabine, Melphalan - Hematologic Malignancies | Phase 2 | Completed | Weill Medical College of Cornell University | 270 | 2012-10-16 | 2026-08-19 |
| Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation Bz (Bortezomib), Len (lenalidomide) - Hematologic Malignancies, Multiple Myeloma | Phase 1 / Phase 2 | Completed | European Myeloma Network B.V. | 49 | 2011-11-01 | 2017-07-06 |
| Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen Preparative Regimen - Hematologic Malignancies, Disorder Related to Transplantation | Phase 2 | Completed | St. Jude Children's Research Hospital | 14 | 2011-06-15 | 2017-06-05 |
| Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Fludarabine, Cytoxan, Total Body Irradiation - Hematologic Malignancies | Phase 1 / Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 87 | 2010-09-01 | 2026-02-19 |
| Umbilical Cord Transplantation for the Elderly Population StemEx - Hematologic Malignancies | Phase 2 | Completed | Loyola University | 18 | 2010-01-01 | 2019-08-21 |
| Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide Cyclophosphamide, Fludarabine, Melphalan - Blood Stem Cell Transplant Failure, Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 176 | 2009-11-05 | 2020-03-25 |
| Cytokine Induced Killer (CIK) Cells In Leukemia Patients in vitro expanded Cytokine Induced Killer (CIK) cells - Hematologic Malignancies | Phase 2 | Completed | A.O. Ospedale Papa Giovanni XXIII | 74 | 2009-07-01 | 2019-01-23 |
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer GSK21110183 - Hematologic Malignancies | Phase 1 / Phase 2 | Completed | Accenture | 73 | 2009-07-01 | 2012-04-04 |
| Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant reduced intensity, related donor stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis) - Hematologic Malignancies, Graft vs Host Disease | Phase 1 / Phase 2 | Completed | Pavan Reddy, MD | 61 | 2009-01-01 | 2014-04-11 |
| Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy StemEx® - Hematologic Malignancies, Acute Myeloid Leukemia | Phase 2 / Phase 3 | Completed | Gamida Cell -Teva Joint Venture Ltd. | 101 | 2007-10-01 | 2015-07-10 |
| Adult Double Cord Blood Transplant Study Cord blood transplantation - Cord Blood Stem Cell Transplantation, Hematologic Malignancies | Phase 2 | Completed | Center for International Blood and Marrow Transplant Research | 56 | 2007-08-01 | 2014-03-10 |
| Phase II Trial of Pentostatin and Targeted Busulfan Pentostatin, Busulfan, Rituximab - Hematologic Malignancies | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 42 | 2007-07-01 | 2014-06-05 |
Showing 20 of 36. Sign in to see all of them.
Hematologic Neoplasms (36) · Graft vs Host Disease (9) · Leukemia (8) · Myelodysplastic Syndromes (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Leukemia, Myeloid, Acute (6) · Lymphoma (6) · Lymphoma, Non-Hodgkin (6) · Hodgkin Disease (5) · Multiple Myeloma (5) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Hematologic Diseases (3) · Myeloproliferative Disorders (3) · Neoplasms, Plasma Cell (3)
Hemic and Lymphatic Diseases (36) · Neoplasms by Site (36) · Neoplasms (34) · Hematologic Diseases (33) · Immune System Diseases (20) · Neoplasms by Histologic Type (17) · Immunoproliferative Disorders (14) · Lymphoproliferative Disorders (14) · Lymphatic Diseases (13) · Bone Marrow Diseases (11) · Disease Attributes (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Chronic Disease (6) · Leukemia, Lymphoid (6)
Tacrolimus (10) · fludarabine (7) · Cyclophosphamide (6) · Mycophenolic Acid (5) · Sirolimus (4) · Whole-Body Irradiation (4) · fludarabine phosphate (4) · Busulfan (3) · Melphalan (3) · Methotrexate (3) · Rituximab (3) · Stem Cell Transplantation (3) · Bortezomib (2) · Mesna (2) · Pentostatin (2)
Dana-Farber Cancer Institute (3) · M.D. Anderson Cancer Center (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2) · A.O. Ospedale Papa Giovanni XXIII (1) · Accenture (1) · Celgene (1) · Center for International Blood and Marrow Transplant Research (1) · Clavis Pharma (1) · Dartmouth-Hitchcock Medical Center (1) · Emory University (1) · European Myeloma Network B.V. (1) · Fate Therapeutics (1) · Gamida Cell -Teva Joint Venture Ltd. (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Janssen Pharmaceutical K.K. (1)
United States (28) · Italy (4) · Germany (3) · Canada (2) · Spain (2) · United Kingdom (2) · Australia (1) · Belgium (1) · France (1) · Hungary (1) · Israel (1) · Japan (1) · Norway (1) · South Korea (1) · Sweden (1)
Patrick Stiff, MD (2) · Agha Mounzer, MD (1) · Alberto Bosi, MD (1) · Alessandro AR Rambaldi, Professor (1) · Alexandra Gomez Arteaga, MD (1) · Amelia Langston, MD (1) · Amr Qudeimat, MD (1) · Attaphol Pawarode, M.D. (1) · Celia Grosskreutz, MD (1) · Christelle Ferra, MD (1) · Christopher J Melani, M.D. (1) · Corey Cutler, MD, MPH (1) · Cristina Arbona, MD (1) · Denis-Claude Roy, MD (1)
PMID 16115130, PMID 16980990, PMID 17162214, PMID 17606446, PMID 18451242, PMID 19462317, PMID 19713456, PMID 20685246, PMID 21868572, PMID 22491731, PMID 23065508, PMID 23524640, PMID 24295572, PMID 25075128, PMID 26869630, PMID 29242852, PMID 29477778, PMID 31135970, PMID 31217161, PMID 34425261, PMID 37882668, PMID 41485109, PMID 41632629
2023 (1), P01CA015396 (1)